AbbVie (ABBV)
Health Care · Biopharmaceutical - Multi-therapeutic
Global biopharmaceutical company with leadership positions in immunology, neuroscience, oncology, and aesthetics targeting complex diseases.
What AbbVie does
AbbVie is a diversified, research-based biopharmaceutical company that discovers, develops, manufactures, and commercializes innovative medicines and therapies globally. The company operates as a single business segment with leadership positions across immunology, neuroscience, oncology, and aesthetics, addressing autoimmune diseases, neurological conditions, cancers, and other complex health issues. AbbVie has a global research and development and supply chain organization, with commercial operations organized by geographic region and therapeutic area.
Themes: ["Immunology","Autoimmune diseases","JAK inhibitors","Biologic therapies","Oncology","Neuroscience","Dermatology","Gastroenterology"]
Fundamentals
- Price$249.91 as of 2026-07-09 close
- Market cap$446.5B as of 2026-07-10
- 1-year return+31.1% as of 2026-07-09 close
- P/E122.84 as of 2026-07-10
- Net margin+5.8% as of 2026-07-10
- Gross margin+72.0% as of 2026-07-10
- ROE+95.6% as of 2026-07-10
- Debt / equity49.22 as of 2026-07-10
- Revenue growth (YoY)+9.5% as of 2026-07-10
- Revenue CAGR (3y)+1.8% SEC XBRL
- Beta0.27 as of 2026-07-10
Dividend: yield +2.7%; 5-year non-decreasing per-share dividend streak (SEC XBRL).
Key risks (from latest filing)
["Significant debt burden with long-term debt of $64.5 billion and accumulated deficit of $17.9 billion, creating financial leverage risk","Patent expiration and loss of exclusivity on key products, particularly immunology franchises, could significantly impact future revenues","Regulatory and approval risks for pipeline therapies, including ongoing development programs requiring regulatory clearance across multiple markets"]
Competitors & peers
Fundamentals: Finnhub, as of 2026-07-10. Filings: SEC EDGAR. Prices are delayed daily-close data.
Last updated 2026-07-09.
Informational only — NOT financial advice. All figures are delayed daily-close data from SEC EDGAR & Finnhub, shown with their as-of date.